The Roles of Metabotropic Glutamate Receptors in Seizures and Epilepsy

Authors: Doherty J.; Dingledine R.

Source: Current Drug Targets-CNS & Neurological Disorders, Volume 1, Number 3, June 2002 , pp. 251-260(11)

Publisher: Bentham Science Publishers

Abstract:

Epilepsy is a disorder that afflicts more than 50 million people worldwide. Current antiepileptic drugs (AEDs), although effective in controlling seizures for the majority of individuals, remain far from ideal as therapeutics. There is a need for new drugs that act at different molecular targets than currently available AEDs and for new therapies designed to block the process of epileptogenesis. Because of their central role in modulating numerous physiological processes in the central nervous system, metabotropic glutamate receptors (mGluRs) have been implicated in the pathophysiology of a variety of neurological conditions including epilepsy. mGluRs represent attractive new targets for therapeutic control of seizures and interruption of the epileptogenic process. We review the involvement of mGluRs in the induction and expression of epileptic seizures, their potential roles in the process of epileptogenesis, and their altered expression and function in the epileptic human brain.

Keywords: glutamate receptor; metabotropic; epilepsy; antiepileptic drugs

Language: English

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1568007023339355

Publication date: 2002-06-01

• CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal will contain a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in neurological and CNS disorders. As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.

• In this: publication
• By this: publisher
• In this Subject: Neurology & Psychiatry ,  Pharmacology
• By this author: Doherty J. ;  Dingledine R.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers